Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in J Cancer Res Clin Oncol Retrieve available abstracts of 184 articles: HTML format

Single Articles

September 2022
1. XIE X, You M, Meng E, Wang S, et al
   Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
   J Cancer Res Clin Oncol. 2022;148:2561-2566.
   PubMed     Abstract available
   
   
   August 2022
2. YAMADA Y, Shimada Y, Makino Y, Kudo Y, et al
   Clinical utility of psoas muscle volume in assessment of sarcopenia in patients with early-stage non-small cell lung cancer.
   J Cancer Res Clin Oncol. 2022 Aug 2. pii: 10.1007/s00432-022-04234.
   PubMed     Abstract available
   
   
   
3. XIE X, Chen X, Luo N, Qi Y, et al
   Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.
   J Cancer Res Clin Oncol. 2022;148:2165-2168.
   PubMed     Abstract available
   
   
   
4. LUO YH, Liu H, Wampfler JA, Tazelaar HD, et al
   Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
   J Cancer Res Clin Oncol. 2022;148:2099-2114.
   PubMed     Abstract available
   
   
   July 2022
5. LI S, Lu X, Zheng D, Chen W, et al
   Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
   J Cancer Res Clin Oncol. 2022 Jul 30. pii: 10.1007/s00432-022-04128.
   PubMed     Abstract available
   
   
   
6. FANG Y, Li Z, Chen H, Zhang T, et al
   Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030.
   J Cancer Res Clin Oncol. 2022 Jul 29. pii: 10.1007/s00432-022-04217.
   PubMed     Abstract available
   
   
   
7. HIGASHIYAMA RI, Horinouchi H, Kuchiba A, Matsumoto Y, et al
   Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.
   J Cancer Res Clin Oncol. 2022 Jul 28. pii: 10.1007/s00432-022-04205.
   PubMed     Abstract available
   
   
   
8. ACHEAMPONG E, Morici M, Abed A, Bowyer S, et al
   Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
   J Cancer Res Clin Oncol. 2022 Jul 28. pii: 10.1007/s00432-022-04202.
   PubMed     Abstract available
   
   
   
9. TAKEUCHI E, Kondo K, Okano Y, Kunishige M, et al
   Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.
   J Cancer Res Clin Oncol. 2022 Jul 24. pii: 10.1007/s00432-022-04215.
   PubMed     Abstract available
   
   
   
10. INOUE Y, Inui N, Karayama M, Asada K, et al
    Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Jul 14. pii: 10.1007/s00432-022-04193.
    PubMed     Abstract available
    
    
    
11. KSIENSKI D, Gupta S, Truong PT, Bone J, et al
    Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic.
    J Cancer Res Clin Oncol. 2022 Jul 14. pii: 10.1007/s00432-022-04181.
    PubMed     Abstract available
    
    
    
12. ZHUO X, Guo H, Ma J, Lai J, et al
    Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.
    J Cancer Res Clin Oncol. 2022 Jul 13. pii: 10.1007/s00432-022-04196.
    PubMed     Abstract available
    
    
    
13. KOWALSKI B, Valaperti A, Bezel P, Steiner UC, et al
    Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.
    J Cancer Res Clin Oncol. 2022;148:1711-1720.
    PubMed     Abstract available
    
    
    June 2022
14. DE GIGLIO A, Deiana C, Di Federico A
    Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.
    J Cancer Res Clin Oncol. 2022 Jun 24. pii: 10.1007/s00432-022-04120.
    PubMed     Abstract available
    
    
    
15. CHANG J, Jing X, Hua Y, Geng K, et al
    Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.
    J Cancer Res Clin Oncol. 2022 Jun 23. pii: 10.1007/s00432-022-04121.
    PubMed     Abstract available
    
    
    
16. HATA T, Sakaguchi C, Hirano K, Kobe H, et al
    Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
    J Cancer Res Clin Oncol. 2022 Jun 23. pii: 10.1007/s00432-022-04125.
    PubMed     Abstract available
    
    
    
17. CAI JS, Lin QY, Dou XM
    Is adjacent lobe invasion an T category upgrade factor for resected non-small cell lung cancer
    J Cancer Res Clin Oncol. 2022 Jun 21. pii: 10.1007/s00432-022-04102.
    PubMed     Abstract available
    
    
    
18. DURSLEWICZ J, Klimaszewska-Wisniewska A, Jozwicki J, Antosik P, et al
    Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2022 Jun 20. pii: 10.1007/s00432-022-04097.
    PubMed     Abstract available
    
    
    
19. WANG Y, Zhang J, Hu B, Wang J, et al
    Influencing factors of lung cancer patients' participation in shared decision-making: a cross-sectional study.
    J Cancer Res Clin Oncol. 2022 Jun 18. pii: 10.1007/s00432-022-04105.
    PubMed     Abstract available
    
    
    
20. GOMPELMANN D, Sinn K, Brugger J, Bernitzky D, et al
    Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.
    J Cancer Res Clin Oncol. 2022 Jun 16. pii: 10.1007/s00432-022-04080.
    PubMed     Abstract available
    
    
    
21. BODOR JN, Bauman JR, Handorf EA, Ross EA, et al
    Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
    J Cancer Res Clin Oncol. 2022 Jun 16. pii: 10.1007/s00432-022-04089.
    PubMed     Abstract available
    
    
    
22. GURBUZ M, Kutlu Y, Akkus E, Koksoy EB, et al
    Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
    J Cancer Res Clin Oncol. 2022 Jun 11. pii: 10.1007/s00432-022-04087.
    PubMed     Abstract available
    
    
    
23. LIU C, Hu C, Chen T, Jiang Y, et al
    The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Jun 7. pii: 10.1007/s00432-022-04071.
    PubMed     Abstract available
    
    
    
24. CANAO F, Ferreira H, Neves NM
    Liposomal formulations for lung cancer treatment in the last two decades: a systematic review.
    J Cancer Res Clin Oncol. 2022 Jun 4. pii: 10.1007/s00432-022-04079.
    PubMed     Abstract available
    
    
    
25. ARNOLD S, Kortland J, Maltseva DV, Nersisyan SA, et al
    Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer.
    J Cancer Res Clin Oncol. 2022;148:1525-1542.
    PubMed     Abstract available
    
    
    
26. WEN Z, Zhang Y, Fu F, Ma Z, et al
    Clinical, pathological and radiologic features of minute pulmonary meningothelial-like nodules.
    J Cancer Res Clin Oncol. 2022;148:1473-1479.
    PubMed     Abstract available
    
    
    
27. ITO M, Miyata Y, Hirano S, Irisuna F, et al
    Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2022;148:1419-1428.
    PubMed     Abstract available
    
    
    May 2022
28. CHENG ES, Weber MF, Steinberg J, Canfell K, et al
    Evaluating risk factors for lung cancer among never-smoking individuals using two Australian studies.
    J Cancer Res Clin Oncol. 2022 May 27. pii: 10.1007/s00432-022-04043.
    PubMed     Abstract available
    
    
    
29. RICCETTI N, Blettner M, Taylor K, Wehler B, et al
    Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS.
    J Cancer Res Clin Oncol. 2022 May 24. pii: 10.1007/s00432-022-03975.
    PubMed     Abstract available
    
    
    
30. LIU X, Ma C, Liu H, Sun Z, et al
    M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 May 20. pii: 10.1007/s00432-022-04032.
    PubMed     Abstract available
    
    
    
31. FAN Y, Sun R, Wang Z, Zhang Y, et al
    Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 May 18. pii: 10.1007/s00432-022-04048.
    PubMed     Abstract available
    
    
    
32. SONG J, Bai L, Zhai J, Xin Z, et al
    Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 May 17. pii: 10.1007/s00432-022-03992.
    PubMed     Abstract available
    
    
    
33. ENGLMEIER F, Bleckmann A, Bruckl W, Griesinger F, et al
    Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.
    J Cancer Res Clin Oncol. 2022 May 9. pii: 10.1007/s00432-022-04034.
    PubMed     Abstract available
    
    
    
34. HAN C, Ding X, Li M, Luo N, et al
    Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    J Cancer Res Clin Oncol. 2022;148:1265-1268.
    PubMed     Abstract available
    
    
    
35. LI T, Fang J, Chu J, Liu X, et al
    In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide.
    J Cancer Res Clin Oncol. 2022;148:1073-1085.
    PubMed     Abstract available
    
    
    
36. ZHANG Y, Men Y, Wang J, Xing P, et al
    Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.
    J Cancer Res Clin Oncol. 2022;148:1137-1146.
    PubMed     Abstract available
    
    
    
37. URAMOTO H, Takiguchi T, Koizumi T, Tanimoto A, et al
    Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.
    J Cancer Res Clin Oncol. 2022;148:1153-1158.
    PubMed     Abstract available
    
    
    April 2022
38. HAN X, Guo J, Tang X, Zhu H, et al
    Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
    J Cancer Res Clin Oncol. 2022 Apr 28. pii: 10.1007/s00432-022-04023.
    PubMed     Abstract available
    
    
    
39. SHEN Y, Lu J, Hu F, Qian J, et al
    Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.
    J Cancer Res Clin Oncol. 2022 Apr 28. pii: 10.1007/s00432-022-03964.
    PubMed     Abstract available
    
    
    
40. TANG X, Huang H, Du P, Wang L, et al
    Intratumoral and peritumoral CT-based radiomics strategy reveals distinct subtypes of non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Apr 17. pii: 10.1007/s00432-022-04015.
    PubMed     Abstract available
    
    
    
41. SHIJUBOU N, Sumi T, Yamada Y, Nakata H, et al
    Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Apr 9. pii: 10.1007/s00432-022-03941.
    PubMed     Abstract available
    
    
    
42. KUDO K, Nishii K, Makimoto G, Ishikawa N, et al
    First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
    J Cancer Res Clin Oncol. 2022 Apr 6. pii: 10.1007/s00432-021-03893.
    PubMed     Abstract available
    
    
    
43. GURSOY P, Tatli AM, Erdem D, Goker E, et al
    Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
    J Cancer Res Clin Oncol. 2022 Apr 5. pii: 10.1007/s00432-022-03984.
    PubMed     Abstract available
    
    
    
44. XU X, Wang H, Yu Z, Chen X, et al
    A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report.
    J Cancer Res Clin Oncol. 2022 Apr 2. pii: 10.1007/s00432-022-03969.
    PubMed     Abstract available
    
    
    
45. CHEN J, Yu Z, Li X, Xu G, et al
    A novel 3' truncated ALK cause ALK + in a patient with minimally invasive adenocarcinoma.
    J Cancer Res Clin Oncol. 2022;148:1005-1006.
    PubMed    
    
    
    March 2022
46. DU W, Chen C, Luo LF, He LN, et al
    Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Mar 18. pii: 10.1007/s00432-022-03978.
    PubMed     Abstract available
    
    
    
47. ZHANG H, Liu M, Du G, Yu B, et al
    Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
    J Cancer Res Clin Oncol. 2022 Mar 17. pii: 10.1007/s00432-022-03940.
    PubMed     Abstract available
    
    
    
48. PURDE MT, Niederer R, Wagner NB, Diem S, et al
    Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    J Cancer Res Clin Oncol. 2022;148:647-656.
    PubMed     Abstract available
    
    
    
49. YAN Y, Gao Z, Han H, Zhao Y, et al
    NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2022;148:565-575.
    PubMed     Abstract available
    
    
    February 2022
50. WU G, Guo L, Gu Y, Huang T, et al
    The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
    J Cancer Res Clin Oncol. 2022 Feb 26. pii: 10.1007/s00432-022-03959.
    PubMed     Abstract available
    
    
    
51. ZHAO Q, Tong J, Liu X, Li S, et al
    Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.
    J Cancer Res Clin Oncol. 2022 Feb 25. pii: 10.1007/s00432-022-03931.
    PubMed     Abstract available
    
    
    
52. SUN C, Liu Y, Zhang P, Wang X, et al
    Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    J Cancer Res Clin Oncol. 2022 Feb 22. pii: 10.1007/s00432-021-03896.
    PubMed     Abstract available
    
    
    
53. LIN X, Deng H, Li S, Xie X, et al
    Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
    J Cancer Res Clin Oncol. 2022 Feb 10. pii: 10.1007/s00432-021-03903.
    PubMed     Abstract available
    
    
    
54. HE C, Wei C, Wen J, Chen S, et al
    Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    J Cancer Res Clin Oncol. 2022;148:321-330.
    PubMed     Abstract available
    
    
    January 2022
55. NIEDER C, Aanes SG, Haukland E
    Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents.
    J Cancer Res Clin Oncol. 2022 Jan 12. pii: 10.1007/s00432-022-03919.
    PubMed     Abstract available
    
    
    
56. CHEN Y, Jin Y, Hu X, Chen M, et al
    Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.
    J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03895.
    PubMed     Abstract available
    
    
    
57. YU TT, Peng XC, Wang MF, Han N, et al
    Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer.
    J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03879.
    PubMed     Abstract available
    
    
    
58. XU Z, Hao X, Yang K, Wang Q, et al
    Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
    J Cancer Res Clin Oncol. 2022 Jan 4. pii: 10.1007/s00432-021-03901.
    PubMed     Abstract available
    
    
    
59. XU B, Cheng H, Li K, Lv Y, et al
    Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naive metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
    J Cancer Res Clin Oncol. 2022 Jan 1. pii: 10.1007/s00432-021-03873.
    PubMed     Abstract available
    
    
    December 2021
60. WANG P, Yin T, Zhao K, Yu J, et al
    Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Dec 8. pii: 10.1007/s00432-021-03877.
    PubMed    
    
    
    
61. WEBER D, Decker M, Schuster M, Folz S, et al
    Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.
    J Cancer Res Clin Oncol. 2021;147:3769-3771.
    PubMed     Abstract available
    
    
    
62. WU H, Zhang Y, Hu H, Li Y, et al
    Ground glass opacity featured lung adenocarcinoma in teenagers.
    J Cancer Res Clin Oncol. 2021;147:3719-3724.
    PubMed     Abstract available
    
    
    
63. NOMURA K, Aokage K, Nakai T, Sakashita S, et al
    Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2021;147:3699-3707.
    PubMed     Abstract available
    
    
    
64. UEDA D, Ito M, Tsutani Y, Gimenez-Capitan A, et al
    Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
    J Cancer Res Clin Oncol. 2021;147:3709-3718.
    PubMed     Abstract available
    
    
    November 2021
65. NEUMANN JM, Freitag H, Hartmann JS, Niehaus K, et al
    Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
    J Cancer Res Clin Oncol. 2021 Nov 28. pii: 10.1007/s00432-021-03834.
    PubMed     Abstract available
    
    
    
66. NAKAMURA R, Yamada T, Morimoto K, Nakao A, et al
    Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Nov 26. pii: 10.1007/s00432-021-03866.
    PubMed     Abstract available
    
    
    
67. WANG P, Yin T, Zhao K, Yu J, et al
    Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Nov 23. pii: 10.1007/s00432-021-03849.
    PubMed     Abstract available
    
    
    
68. CHEN Q, Li Y, Zhang W, Wang C, et al
    Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    J Cancer Res Clin Oncol. 2021 Nov 19. pii: 10.1007/s00432-021-03858.
    PubMed     Abstract available
    
    
    
69. GAO X, Peng L, Zhang L, Huang K, et al
    Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Nov 8. pii: 10.1007/s00432-021-03848.
    PubMed     Abstract available
    
    
    
70. FANG X, Wu G, Hua J, Zhao P, et al
    TCF-1(+) PD-1(+) CD8(+)T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Nov 2. pii: 10.1007/s00432-021-03845.
    PubMed     Abstract available
    
    
    
71. UHLENBRUCH M, Kruger S
    Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy.
    J Cancer Res Clin Oncol. 2021 Nov 1. pii: 10.1007/s00432-021-03734.
    PubMed     Abstract available
    
    
    October 2021
72. BAI R, Chen X, Song W, Tian H, et al
    Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.
    J Cancer Res Clin Oncol. 2021 Oct 26. pii: 10.1007/s00432-021-03840.
    PubMed     Abstract available
    
    
    
73. ZHOU L, Wang X, Lu J, Fu X, et al
    EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03800.
    PubMed     Abstract available
    
    
    
74. ZHAO Y, Wang H, He C
    Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03828.
    PubMed     Abstract available
    
    
    
75. ZENG J, Li X, Liang L, Duan H, et al
    Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion.
    J Cancer Res Clin Oncol. 2021 Oct 12. pii: 10.1007/s00432-021-03819.
    PubMed     Abstract available
    
    
    September 2021
76. ROCHA ALG, da Conceicao MAM, da Cunha Sequeira Mano FXP, Martins HC, et al
    Metabolic active tumour volume quantified on [(18)F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Sep 27. pii: 10.1007/s00432-021-03799.
    PubMed     Abstract available
    
    
    
77. TANG X, Li Y, Qian WL, Yan WF, et al
    A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.
    J Cancer Res Clin Oncol. 2021 Sep 18. pii: 10.1007/s00432-021-03797.
    PubMed     Abstract available
    
    
    
78. ZHONG Y, Wu Q, Wu S, Xie X, et al
    Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants.
    J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03798.
    PubMed     Abstract available
    
    
    
79. OMORI S, Muramatsu K, Kawata T, Miyawaki E, et al
    Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
    J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03784.
    PubMed     Abstract available
    
    
    
80. POMPILI C, Dalmia S, McLennan Battleday F, Rogers Z, et al
    Factors influencing patient satisfaction after treatments for early-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Sep 13. pii: 10.1007/s00432-021-03795.
    PubMed     Abstract available
    
    
    
81. MORIMOTO K, Uchino J, Yokoi T, Kijima T, et al
    Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
    J Cancer Res Clin Oncol. 2021 Sep 12. pii: 10.1007/s00432-021-03782.
    PubMed     Abstract available
    
    
    
82. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Efficacy and safety of transbronchial microwave ablation therapy under moderate sedation in malignant central airway obstruction patients with respiratory failure: a single-institution retrospective study.
    J Cancer Res Clin Oncol. 2021;147:2751-2757.
    PubMed     Abstract available
    
    
    
83. GROGG JB, Fronzaroli JN, Oliveira P, Bode PK, et al
    Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data.
    J Cancer Res Clin Oncol. 2021;147:2671-2679.
    PubMed     Abstract available
    
    
    August 2021
84. WANG F, Jin F, Cheng B, Zhang Y, et al
    The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Aug 6. pii: 10.1007/s00432-021-03752.
    PubMed     Abstract available
    
    
    
85. IANZA A, Di Chicco A, Biagi C, Giudici F, et al
    EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.
    J Cancer Res Clin Oncol. 2021;147:2301-2307.
    PubMed     Abstract available
    
    
    
86. LI P, Hou F, Wang S, Luo N, et al
    A novel NECTIN4-NTRK1 fusion identified in a lung squamous cell carcinoma patient with MSI-H.
    J Cancer Res Clin Oncol. 2021;147:2483-2486.
    PubMed    
    
    
    July 2021
87. HIZAL M, Bilgin B, Paksoy N, Acikgoz O, et al
    The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
    J Cancer Res Clin Oncol. 2021 Jul 31. pii: 10.1007/s00432-021-03748.
    PubMed     Abstract available
    
    
    
88. YANG Z, Yu R, Deng W, Wang W, et al
    Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
    J Cancer Res Clin Oncol. 2021 Jul 29. pii: 10.1007/s00432-021-03740.
    PubMed     Abstract available
    
    
    
89. SU Z, Jiang Y, Li C, Zhong R, et al
    Relationship between lung function and lung cancer risk: a pooled analysis of cohorts plus Mendelian randomization study.
    J Cancer Res Clin Oncol. 2021 Jul 27. pii: 10.1007/s00432-021-03619.
    PubMed     Abstract available
    
    
    
90. OTA T, Kirita K, Matsuzawa R, Udagawa H, et al
    Correction to: Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
    J Cancer Res Clin Oncol. 2021 Jul 23. pii: 10.1007/s00432-021-03737.
    PubMed    
    
    
    
91. SUN J, Zhang J, Hu H, Qin H, et al
    Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer.
    J Cancer Res Clin Oncol. 2021 Jul 21. pii: 10.1007/s00432-021-03735.
    PubMed     Abstract available
    
    
    
92. BRANCHER S, Ribeiro AE, Toporcov TN, Weiderpass E, et al
    The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials.
    J Cancer Res Clin Oncol. 2021 Jul 15. pii: 10.1007/s00432-021-03728.
    PubMed     Abstract available
    
    
    
93. GUO R, Zhang Y, Ma Z, Deng C, et al
    Overuse of follow-up chest computed tomography in patients with incidentally identified nodules suspicious for lung cancer.
    J Cancer Res Clin Oncol. 2021 Jul 8. pii: 10.1007/s00432-021-03692.
    PubMed     Abstract available
    
    
    
94. HE X, Ma X, Wang C, Luan M, et al
    The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo.
    J Cancer Res Clin Oncol. 2021;147:1927-1934.
    PubMed     Abstract available
    
    
    
95. LIU J, Hao J, Niu Y, Wu X, et al
    Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients.
    J Cancer Res Clin Oncol. 2021;147:2079-2092.
    PubMed     Abstract available
    
    
    June 2021
96. DOU Y, Duan Q, Qi C, Hou L, et al
    An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2021;147:1865-1867.
    PubMed     Abstract available
    
    
    May 2021
97. SHEN Z, Chen C, Sun J, Huang J, et al
    The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
    J Cancer Res Clin Oncol. 2021 May 26. pii: 10.1007/s00432-021-03640.
    PubMed     Abstract available
    
    
    
98. ZHANG Y, Zhang Z, Ding Y, Fang Y, et al
    Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 May 25. pii: 10.1007/s00432-021-03613.
    PubMed     Abstract available
    
    
    
99. ZHAO Y, Liu Y, Li S, Peng Z, et al
    Role of lung and gut microbiota on lung cancer pathogenesis.
    J Cancer Res Clin Oncol. 2021 May 20. pii: 10.1007/s00432-021-03644.
    PubMed     Abstract available
    
    
    
100. DAI Y, Zhong F, Liu W, Song Q, et al
     Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.
     J Cancer Res Clin Oncol. 2021;147:1379-1388.
     PubMed     Abstract available
     
     
     
101. FRANZESE C, Badalamenti M, Teriaca A, De Virgilio A, et al
     Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
     J Cancer Res Clin Oncol. 2021;147:1307-1313.
     PubMed     Abstract available
     
     
     April 2021
102. LEONETTI A, Carbone D, Gregori A, Tiseo M, et al
     A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
     J Cancer Res Clin Oncol. 2021 Apr 26. pii: 10.1007/s00432-021-03647.
     PubMed    
     
     
     
103. QIU X, Zhang H, Zhao Y, Zhao J, et al
     Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer.
     J Cancer Res Clin Oncol. 2021 Apr 24. pii: 10.1007/s00432-021-03648.
     PubMed     Abstract available
     
     
     
104. NOUNU A, Walker V, Richmond RC
     Correction to: Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".
     J Cancer Res Clin Oncol. 2021 Apr 11. pii: 10.1007/s00432-021-03636.
     PubMed    
     
     
     
105. WEI T, Song J, Liang K, Li L, et al
     Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
     J Cancer Res Clin Oncol. 2021;147:1049-1064.
     PubMed     Abstract available
     
     
     
106. ZHANG G, Cao Y, Zhang J, Zhao Z, et al
     Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.
     J Cancer Res Clin Oncol. 2021;147:1169-1178.
     PubMed     Abstract available
     
     
     March 2021
107. HARA N, Ichihara E, Harada D, Inoue K, et al
     Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
     J Cancer Res Clin Oncol. 2021 Mar 29. pii: 10.1007/s00432-021-03615.
     PubMed     Abstract available
     
     
     
108. PATEL MA, Fazli Y, Sivakumar S, Dennis C, et al
     Brachytherapy vs external beam therapy among NSCLC patients undergoing limited surgical resection.
     J Cancer Res Clin Oncol. 2021;147:853-861.
     PubMed     Abstract available
     
     
     
109. HUANG D, Cui P, Huang Z, Wu Z, et al
     Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2021;147:881-891.
     PubMed     Abstract available
     
     
     
110. LIN M, Qu M, Huang W, Liu T, et al
     Clinical effectiveness of percutaneous vertebroplasty in conjunction with postoperative radiotherapy in the treatment of spinal metastases.
     J Cancer Res Clin Oncol. 2021;147:835-844.
     PubMed     Abstract available
     
     
     February 2021
111. FENG M, Ye X, Chen B, Zhang J, et al
     Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer.
     J Cancer Res Clin Oncol. 2021 Feb 6. pii: 10.1007/s00432-021-03517.
     PubMed     Abstract available
     
     
     
112. BILGIN B, Sendur MAN, Yucel S, Hizal M, et al
     The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.
     J Cancer Res Clin Oncol. 2021 Feb 2. pii: 10.1007/s00432-021-03546.
     PubMed     Abstract available
     
     
     
113. PARK JH, You GL, Ahn MJ, Kim SW, et al
     Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
     J Cancer Res Clin Oncol. 2021 Feb 1. pii: 10.1007/s00432-021-03527.
     PubMed     Abstract available
     
     
     
114. BI Y, Jiang Y, Li X, Hou G, et al
     Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/beta-catenin signaling and autophagy.
     J Cancer Res Clin Oncol. 2021;147:499-505.
     PubMed     Abstract available
     
     
     
115. CHANG Y, Zhao C, Ding H, Wang T, et al
     Serum factor(s) from lung adenocarcinoma patients regulates the molecular clock expression.
     J Cancer Res Clin Oncol. 2021;147:493-498.
     PubMed     Abstract available
     
     
     
116. CAROSIO R, Fontana V, Mastracci L, Ferro P, et al
     Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
     J Cancer Res Clin Oncol. 2021;147:459-468.
     PubMed     Abstract available
     
     
     January 2021
117. LI X, Liu L, Song X, Wang K, et al
     TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction.
     J Cancer Res Clin Oncol. 2021 Jan 29. pii: 10.1007/s00432-020-03502.
     PubMed     Abstract available
     
     
     
118. YANG M, Li Z, Tao J, Hu H, et al
     Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells.
     J Cancer Res Clin Oncol. 2021 Jan 20. pii: 10.1007/s00432-021-03510.
     PubMed     Abstract available
     
     
     
119. NOUNU A, Walker V, Richmond RC
     Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".
     J Cancer Res Clin Oncol. 2021 Jan 12. pii: 10.1007/s00432-020-03508.
     PubMed    
     
     
     
120. BILGIN B, Sendur MAN, Yucel S, Celik E, et al
     Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
     J Cancer Res Clin Oncol. 2021 Jan 12. pii: 10.1007/s00432-020-03501.
     PubMed     Abstract available
     
     
     
121. FU F, Zhang Y, Gao Z, Zhao Y, et al
     Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Jan 4. pii: 10.1007/s00432-020-03477.
     PubMed     Abstract available
     
     
     
122. XIN S, Fang W, Li J, Li D, et al
     Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 Jan 2. pii: 10.1007/s00432-020-03476.
     PubMed     Abstract available
     
     
     
123. MATSUBARA T, Yamaguchi M, Jinnouchi M, Takamori S, et al
     Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis.
     J Cancer Res Clin Oncol. 2021 Jan 2. pii: 10.1007/s00432-020-03478.
     PubMed     Abstract available
     
     
     
124. WU Z, Huang T, Zhang S, Cheng D, et al
     A prediction model to evaluate the pretest risk of malignancy in solitary pulmonary nodules: evidence from a large Chinese southwestern population.
     J Cancer Res Clin Oncol. 2021;147:275-285.
     PubMed     Abstract available
     
     
     
125. MASUDA K, Horinouchi H, Tanaka M, Higashiyama R, et al
     Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
     J Cancer Res Clin Oncol. 2021;147:245-251.
     PubMed     Abstract available
     
     
     December 2020
126. NADLER E, Arondekar B, Aguilar KM, Zhou J, et al
     Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
     J Cancer Res Clin Oncol. 2020 Dec 2. pii: 10.1007/s00432-020-03414.
     PubMed     Abstract available
     
     
     November 2020
127. RACHOW T, Schiffl H, Lang SM
     Risk of lung cancer and renin-angiotensin blockade: a concise review.
     J Cancer Res Clin Oncol. 2020 Nov 24. pii: 10.1007/s00432-020-03445.
     PubMed     Abstract available
     
     
     
128. SHU Z, Dong B, Shi L, Shen W, et al
     Correction to: Stereotactic body radiotherapy for elderly patients (>/= 75 years) with earlystage nonsmall cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Nov 23. pii: 10.1007/s00432-020-03469.
     PubMed     Abstract available
     
     
     
129. HAO S, Liu J, Ma J
     Further discussion on the association between desmoglein 2 and tumor size of non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Nov 22. pii: 10.1007/s00432-020-03465.
     PubMed     Abstract available
     
     
     
130. ZHENG Q, Huang Y, Zeng X, Chen X, et al
     Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
     J Cancer Res Clin Oncol. 2020 Nov 16. pii: 10.1007/s00432-020-03444.
     PubMed     Abstract available
     
     
     
131. ARAGAKI M, Hida Y, Kato T, Fujiwara-Kuroda A, et al
     Feasibility of limited resection for peripheral small-sized non-small cell lung cancer: a retrospective single-center-based study.
     J Cancer Res Clin Oncol. 2020 Nov 5. pii: 10.1007/s00432-020-03441.
     PubMed     Abstract available
     
     
     
132. CHEN S, Bao Y, Xu J, Zhang X, et al
     Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis.
     J Cancer Res Clin Oncol. 2020;146:2913-2935.
     PubMed     Abstract available
     
     
     
133. WANG F, Zhao N, Gao G, Deng HB, et al
     Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2020;146:2851-2859.
     PubMed     Abstract available
     
     
     
134. YANG J, Wu Z, Chen Y, Hu C, et al
     Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer.
     J Cancer Res Clin Oncol. 2020 Nov 1. pii: 10.1007/s00432-020-03434.
     PubMed     Abstract available
     
     
     October 2020
135. LI L, Pan Y, Mo X, Wei T, et al
     A novel metastatic promoter CEMIP and its downstream molecular targets and signaling pathway of cellular migration and invasion in SCLC cells based on proteome analysis.
     J Cancer Res Clin Oncol. 2020;146:2519-2534.
     PubMed     Abstract available
     
     
     
136. TAKADA K, Toyokawa G, Kinoshita F, Jogo T, et al
     Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
     J Cancer Res Clin Oncol. 2020;146:2639-2650.
     PubMed     Abstract available
     
     
     September 2020
137. SAKAI T, Udagawa H, Matsumoto S, Yoh K, et al
     Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Sep 30. pii: 10.1007/s00432-020-03413.
     PubMed     Abstract available
     
     
     
138. XIAN W, Shen J, Zhou H, Liu J, et al
     Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer.
     J Cancer Res Clin Oncol. 2020 Sep 28. pii: 10.1007/s00432-020-03409.
     PubMed     Abstract available
     
     
     
139. JIANG Y, Su Z, Li C, Wang R, et al
     Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.
     J Cancer Res Clin Oncol. 2020 Sep 23. pii: 10.1007/s00432-020-03394.
     PubMed     Abstract available
     
     
     
140. LI Q, Zhu X, Song W, Peng X, et al
     The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.
     J Cancer Res Clin Oncol. 2020 Sep 5. pii: 10.1007/s00432-020-03379.
     PubMed     Abstract available
     
     
     
141. ZHOU X, Xu X, Tian Z, Xu WY, et al
     Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing.
     J Cancer Res Clin Oncol. 2020;146:2277-2287.
     PubMed     Abstract available
     
     
     
142. LIU J, Yang X, Zhang L, Yang B, et al
     Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2020;146:2299-2310.
     PubMed     Abstract available
     
     
     
143. FRANZESE C, Bonu ML, Comito T, Clerici E, et al
     Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
     J Cancer Res Clin Oncol. 2020;146:2289-2297.
     PubMed     Abstract available
     
     
     
144. KIM SA, Kim JW, Suh KJ, Chang W, et al
     Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
     J Cancer Res Clin Oncol. 2020;146:2399-2410.
     PubMed     Abstract available
     
     
     
145. ZHANG Y, Deng C, Ma X, Gao Z, et al
     Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy.
     J Cancer Res Clin Oncol. 2020;146:2411-2417.
     PubMed     Abstract available
     
     
     August 2020
146. ZHOU L, Zhang M, Li R, Xue J, et al
     Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
     J Cancer Res Clin Oncol. 2020 Aug 28. pii: 10.1007/s00432-020-03360.
     PubMed     Abstract available
     
     
     
147. MA X, Wang S, Zhang Y, Wei H, et al
     Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
     J Cancer Res Clin Oncol. 2020 Aug 27. pii: 10.1007/s00432-020-03362.
     PubMed     Abstract available
     
     
     
148. DU TQ, Li X, Zhong WS, Tian JD, et al
     Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost.
     J Cancer Res Clin Oncol. 2020 Aug 26. pii: 10.1007/s00432-020-03359.
     PubMed     Abstract available
     
     
     
149. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
     Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
     J Cancer Res Clin Oncol. 2020 Aug 6. pii: 10.1007/s00432-020-03344.
     PubMed     Abstract available
     
     
     July 2020
150. CHEN SS, Li K, Wu J, Peng ZY, et al
     Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Jul 20. pii: 10.1007/s00432-020-03325.
     PubMed     Abstract available
     
     
     
151. LATHWAL A, Kumar R, Arora C, Raghava GPS, et al
     Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
     J Cancer Res Clin Oncol. 2020 Jul 14. pii: 10.1007/s00432-020-03318.
     PubMed     Abstract available
     
     
     
152. BIAN J, Yan K, Liu N, Xu X, et al
     Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Jul 13. pii: 10.1007/s00432-020-03244.
     PubMed     Abstract available
     
     
     
153. HUO Y, Guo Z, Gao X, Liu Z, et al
     Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules.
     J Cancer Res Clin Oncol. 2020 Jul 9. pii: 10.1007/s00432-020-03309.
     PubMed     Abstract available
     
     
     
154. LANDRE T, Des Guetz G, Chouahnia K, Duchemann B, et al
     First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
     J Cancer Res Clin Oncol. 2020 Jul 7. pii: 10.1007/s00432-020-03311.
     PubMed     Abstract available
     
     
     
155. KO KH, Huang HK, Chen YI, Chang H, et al
     Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy.
     J Cancer Res Clin Oncol. 2020 Jul 6. pii: 10.1007/s00432-020-03310.
     PubMed     Abstract available
     
     
     
156. ZENG Y, Li N, Liu W, Zeng M, et al
     Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Jul 5. pii: 10.1007/s00432-020-03288.
     PubMed     Abstract available
     
     
     
157. ZHAO Y, Pan Y, Cheng C, Zheng D, et al
     EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
     J Cancer Res Clin Oncol. 2020;146:1781-1789.
     PubMed     Abstract available
     
     
     
158. JU Q, Zhao YJ, Ma S, Li XM, et al
     Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.
     J Cancer Res Clin Oncol. 2020;146:1711-1723.
     PubMed     Abstract available
     
     
     June 2020
159. LI WQ, Cui JW
     Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments.
     J Cancer Res Clin Oncol. 2020 Jun 28. pii: 10.1007/s00432-020-03296.
     PubMed     Abstract available
     
     
     
160. KIM SH, Choi CM, Lee DH, Kim SW, et al
     Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
     J Cancer Res Clin Oncol. 2020 Jun 24. pii: 10.1007/s00432-020-03293.
     PubMed     Abstract available
     
     
     
161. XIE J, Zhang X, Hu S, Peng WD, et al
     Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
     J Cancer Res Clin Oncol. 2020 Jun 12. pii: 10.1007/s00432-020-03276.
     PubMed     Abstract available
     
     
     
162. ZHOU H, Sun Y, Xiu W, Han J, et al
     Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
     J Cancer Res Clin Oncol. 2020 Jun 9. pii: 10.1007/s00432-020-03282.
     PubMed     Abstract available
     
     
     
163. HUI Z, Wei F, Ren H, Xu W, et al
     Primary tumor standardized uptake value (SUVmax) measured on (18)F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03240.
     PubMed     Abstract available
     
     
     
164. LUO G, Tang M, Zhao Q, Lu L, et al
     Bone marrow adipocytes enhance osteolytic bone destruction by activating 1q21.3(S100A7/8/9-IL6R)-TLR4 pathway in lung cancer.
     J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03277.
     PubMed     Abstract available
     
     
     
165. ZHAO M, Chen Z, Zheng Y, Liang J, et al
     Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
     J Cancer Res Clin Oncol. 2020;146:1463-1472.
     PubMed     Abstract available
     
     
     
166. WEN Z, Zhao Y, Fu F, Hu H, et al
     Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter.
     J Cancer Res Clin Oncol. 2020;146:1603-1613.
     PubMed     Abstract available
     
     
     May 2020
167. AARNINK A, Fumet JD, Favier L, Truntzer C, et al
     Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
     J Cancer Res Clin Oncol. 2020 May 30. pii: 10.1007/s00432-020-03262.
     PubMed     Abstract available
     
     
     
168. HAKOZAKI T, Hosomi Y, Shimizu A, Kitadai R, et al
     Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
     J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03252.
     PubMed     Abstract available
     
     
     
169. HAKOZAKI T, Hosomi Y, Kitadai R, Kitagawa S, et al
     Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.
     J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03271.
     PubMed     Abstract available
     
     
     
170. ESAGIAN SM, Grigoriadou GIota, Nikas IP, Boikou V, et al
     Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.
     J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03267.
     PubMed     Abstract available
     
     
     
171. ZHU HZ, Fang CJ, Guo Y, Zhang Q, et al
     Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study.
     J Cancer Res Clin Oncol. 2020 May 23. pii: 10.1007/s00432-020-03246.
     PubMed     Abstract available
     
     
     
172. MU Y, Hao X, Xing P, Hu X, et al
     Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
     J Cancer Res Clin Oncol. 2020 May 8. pii: 10.1007/s00432-020-03239.
     PubMed     Abstract available
     
     
     
173. RANA RH, Alam F, Alam K, Gow J, et al
     Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review.
     J Cancer Res Clin Oncol. 2020;146:1169-1196.
     PubMed     Abstract available
     
     
     
174. CHEN YY, Huang YJ, Huang HK, Chang H, et al
     The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer.
     J Cancer Res Clin Oncol. 2020;146:1299-1306.
     PubMed     Abstract available
     
     
     
175. OKI T, Aokage K, Nomura S, Tane K, et al
     Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung.
     J Cancer Res Clin Oncol. 2020;146:1291-1298.
     PubMed     Abstract available
     
     
     
176. ZHOU C, Li W, Shao J, Zhao J, et al
     Thoracic solitary fibrous tumors: an analysis of 70 patients who underwent surgical resection in a single institution.
     J Cancer Res Clin Oncol. 2020;146:1245-1252.
     PubMed     Abstract available
     
     
     
177. FRANZESE C, Comito T, Franceschini D, Loi M, et al
     Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
     J Cancer Res Clin Oncol. 2020;146:1227-1234.
     PubMed     Abstract available
     
     
     April 2020
178. LI A, Cao W, Liu X, Zhang Y, et al
     Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
     J Cancer Res Clin Oncol. 2020 Apr 27. pii: 10.1007/s00432-020-03228.
     PubMed     Abstract available
     
     
     
179. LIU J, Mao G, Li Y, Tao L, et al
     Targeted deep sequencing helps distinguish independent primary tumors from intrapulmonary metastasis for lung cancer diagnosis.
     J Cancer Res Clin Oncol. 2020 Apr 24. pii: 10.1007/s00432-020-03227.
     PubMed     Abstract available
     
     
     
180. LI N, Zeng Y, Huang J
     Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
     J Cancer Res Clin Oncol. 2020 Apr 7. pii: 10.1007/s00432-020-03188.
     PubMed     Abstract available
     
     
     
181. YOU H, Zhang YZ, Lai HL, Li D, et al
     Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer.
     J Cancer Res Clin Oncol. 2020 Apr 4. pii: 10.1007/s00432-020-03189.
     PubMed     Abstract available
     
     
     
182. GUO W, Sun S, Guo L, Song P, et al
     Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics.
     J Cancer Res Clin Oncol. 2020;146:821-841.
     PubMed     Abstract available
     
     
     
183. MORMILE R
     Hyperthermia, positive feedback loop with IL-6 and risk of NSCLC progression: a tangle to unravel?
     J Cancer Res Clin Oncol. 2020;146:1101-1102.
     PubMed     Abstract available
     
     
     March 2020
184. CHEN H, Wang A, Wang J, He Z, et al
     Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
     J Cancer Res Clin Oncol. 2020 Mar 27. pii: 10.1007/s00432-020-03192.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: